Speakers (in order of appearance)

Albert-László Barabási, Ph.D.

Northeastern University

Albert-László Barabási is both the Robert Gray Dodge Professor of Network Science and a Distinguished University Professor at Northeastern University, where he directs the Center for Complex Network Research, and holds appointments in the Departments of Physics and Computer Science, as well as in the Department of Medicine, Harvard Medical School and Brigham and Women Hospital, and is a member of the Center for Cancer Systems Biology at Dana Farber Cancer Institute. A Hungarian born native of Transylvania, Romania, he received his Masters in Theoretical Physics at the Eötvös University in Budapest, Hungary and was awarded a Ph.D. three years later at Boston University. Barabási latest book is "Bursts: The Hidden Pattern Behind Everything We Do" (Dutton, 2010) available in five languages. He has also authored "Linked: The New Science of Networks" (Perseus, 2002), currently available in eleven languages, and is the co-editor of "The Structure and Dynamics of Networks" (Princeton, 2005). His work lead to the discovery of scale-free networks in 1999, and proposed the Barabási -Albert model to explain their widespread emergence in natural, technological and social systems, from the cellular telephone to the WWW or online communities.

Barabási is a Fellow of the American Physical Society. In 2005 he was awarded the FEBS Anniversary Prize for Systems Biology and in 2006 the John von Neumann Medal by the John von Neumann Computer Society from Hungary, for outstanding achievements in computer-related science and technology. In 2004 he was elected into the Hungarian Academy of Sciences and in 2007 into the Academia Europaea.  He received the C&C Prize from the NEC C&C Foundation in 2008. In 2009 APS chose him Outstanding Referee and the US National Academies of Sciences awarded him the 2009 Cozzarelli Prize. In 2011 Barabási was awarded the Lagrange Prize-CRT Foundation for his contributions to complex systems, awarded Doctor Honoris Causa from Universidad Politécnica de Madrid, became an elected Fellow in AAAS (Physics) and is a 2013 Fellow of the Massachusetts Academy of Sciences.

Jane Driver, M.D., M.P.H.

Brigham and Women's Hospital

Jane (Jenny) A. Driver, MD, MPH is Associate Director of the VA Boston GRECC and a member of the Division of Aging, Brigham and Women’s Hospital and the Division of Medical Oncology, Dana Farber Cancer Institute.  She is an Assistant Professor at Harvard Medical School. Trained as both a geriatrician and an oncologist, her research focuses on the epidemiology, prediction and prevention of cancer and neurodegenerative disease. Dr. Driver has received research grants from the Veterans Affairs, Hartford Foundation, the Parkinson’s Disease Foundation and Harvard Medical School. She is currently exploring the nexus of cancer and neurodegenerative disease in order to identify new therapies for both conditions. This includes pursuit of novel therapies based on the protein Pin1, which is upregulated in cancer and downregulated in Alzheimer’s disease, and metabolic approaches to prevention of both diseases.

Dr. Driver also has a focus on clinical innovation and has developed new models of transitional care. She has also created a special clinical and research program for older patients with hematologic malignancies at the Dana Farber Research Institute.  Dr. Driver teaches medical students, medical residents, geriatric fellows, and provides research mentorship for trainees and young faculty in both geriatrics and oncology.

Nicholas Wood, Ph.D.

University College London

Nicholas Wood is Galton Professor of Genetics and Research Director of the UCL Genetics Institute. He is currently a Consultant Neurologist and the UCLH Biomedical Research Council Neuroscience Programme Director. He qualified in medicine from Birmingham University in 1986 and undertook doctoral research at the University of Cambridge and was awarded a PhD in 1994.  He trained in clinical neurology in Cambridge and the National Hospital for Neurology and Neurosurgery, Queen Square, London.  He was appointed Senior Lecturer (UCL Institute of Neurology) and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery in 1995. In 2004 he was elected a Fellow of the Academy of Medical Sciences and in 2012 a Fellow of the American Neurological Association. His primary research interest is the genetics of neurological disease with an emphasis on the genetics of Parkinson’s disease and the ataxias. Recently he and his colleagues have started to explore potential linkages between neurodegeneration and pathogens to cancer. He has published over 370 peer-reviewed articles and is on the board of several international neuroscience journals.

Nathan Price, Ph.D.

Institute for Systems Biology

Dr. Price is Professor & Associate Director of the Institute for Systems Biology. He is Co-Founder and on the Board of Directors of Arivale (“Your Scientific Path to Wellness”), which was recently named as Geekwire‘s 2016 “Startup of the Year.” Nathan has won numerous awards for his scientific work, including an NIH Howard Temin Pathway to Independence Award, an NSF CAREER award, a young investigator award from the Roy J. Carver Charitable Trust, and he was named as one of the inaugural “Tomorrow’s PIs” by Genome Technology and as a Camille Dreyfus Teacher-Scholar. Most recently, he received the 2016 Grace A. Goldsmith Award from the American College of Nutrition for his work in scientific wellness. Dr. Price serves on editorial boards for many leading scientific journals including Science Translational Medicine and Cell Systems. Dr. Price served on the National Academy of Medicine committee to review omics-based tests to predict clinical outcome in clinical trials. Dr. Price also serves on scientific advisory boards for a number of companies and institutes including Habit (a personalized nutrition company), Trelys (a metabolic engineering company),Cleveland Clinic’s Center for Functional Medicine, the Novo Nordisk Foundation Center for Biosustainability, the P4 Medicine Institute, the University of Washington’s Public Health Genomics Institute, the UW Multidisciplinary Learning Disability Center, and the DOE ENIGMA program at UC Berkeley/LBNL/MIT. He is also a fellow of the European Society of Preventive Medicine.

Jeffrey Iliff, Ph.D.

Oregon Health & Science University

Dr. Iliff is an Assistant Professor and Director of Basic Science Research in the Department of Anesthesiology and Perioperative Medicine at Oregon Health & Science University. As a postdoc in the lab of Maiken Nedergaard at the University of Rochester Medical Center, Dr. Iliff helped to define the ‘glymphatic’ system, a brain-wide network of perivascular spaces that facilitates the clearance of wastes, including amyloid beta and tau, from the brain interstitium. Iliff’s recent studies have shown that the glymphatic system fails in the aging brain and in the young brain after traumatic brain injury (TBI). These studies suggest that impairment of glymphatic function may be one factor that renders the aging brain vulnerable to protein aggregation and neurodegeneration and may link brain trauma early in life with the development of dementia in the decades that follow. In 2015 Dr. Iliff was named an Allen Distinguished Investigator for his innovative research on Alzheimer's disease. Ongoing work in his lab seeks to define the molecular and cellular underpinnings of impaired glymphatic function in the aging and post-traumatic brain, and to define how the glymphatic system interacts with the cerebrospinal fluid compartment and cranial lymphatic vasculature to regulate peripheral immune surveillance of the CNS in both health and disease. Through collaborations with the OHSU Advanced Imaging Research Center and NIA Oregon Alzheimer’s Disease Center, his group lastly seeks to extend these findings into clinical Alzheimer’s disease and post-traumatic populations.

Peter Douglas, Ph.D.

UT Southwestern Medical Center

Peter Douglas, Ph.D., was born in San Antonio, Texas, and lived in Dallas, Chapel Hill, North Carolina, and St. Louis, Missouri, before receiving his bachelor’s degree in biochemistry from the University of Colorado Boulder. Peter earned his Ph.D. from the University of North Carolina Chapel Hill. As a graduate student in the laboratory of Dr. Douglas Cyr, Peter used different methods in biochemistry, genetics, and cell biology to understand the mechanisms by which protein homeostasis machinery detoxifies unstable, aggregation-prone proteins. During this time, he was awarded a predoctoral fellowship from the American Heart Association.

Peter completed his postdoctoral studies in the laboratory of Dr. Andrew Dillin at the Salk Institute in La Jolla, California, and the University of California Berkeley where he studied how cellular stress response pathways regulate organismal health and the aging process. During this time, he was awarded fellowships from the National Institute of Health on the Neuroplasticity of Aging and the George E. Hewitt Medical Foundation. He also received a Pathway to Independence Award (K99/R00) from the National Institute of Health.

In 2015, Peter joined the faculty at UT Southwestern Medical Center as an assistant professor in the Department of Molecular Biology and is a member of the Center for Regenerative Science and Medicine. Ongoing research in the Douglas lab seeks to understand how stress response pathways alter cell physiology, and ultimately influence the aging process and human disease.

Vamsi Mootha, M.D.

Harvard Medical School

Vamsi Mootha is an Investigator of the Howard Hughes Medical Institute and Professor of Systems Biology at Harvard Medical School.  He directs a research laboratory based at Massachusetts General Hospital.
Mootha’s research is focused on mitochondria, often termed the "powerhouses" of the cell.  Mootha’s group has used proteomics and computation to define all the molecular components of this organelle.  He and his collaborators have used this inventory to discover more than 15 disease genes underlying rare metabolic syndromes.  His group has also discovered alterations in mitochondria associated with common diseases such as diabetes and cancer.  Ongoing work is aimed at devising novel therapeutic approaches for preventing and reversing mitochondrial dysfunction.
Mootha received his undergraduate degree in mathematical and computational science at Stanford University and his M.D. from the Harvard-MIT Division of Health Sciences and Technology. He subsequently completed his internship and residency in internal medicine at Brigham and Women's Hospital, after which he completed postdoctoral training at the Whitehead Institute.  He has been on the Harvard faculty since 2003. 
He has received a number awards, including a MacArthur Prize, election to the National Academy of Sciences, and a Padma Shri from the Government of India.

Diane Barber, Ph.D.

University of California, San Francisco

Dr. Diane Barber is an Endowed Professor and Chair of the Department of Cell and Tissue Biology at the University of California San Francisco. She received her PhD from the University of California Los Angeles in 1985 and was a postdoctoral fellow at the University of Massachusetts Medical Center. Her first faculty appointment was at Yale University before she moved to UCSF in 1993. She heads a cell biology laboratory investigating how intracellular pH and actin filament dynamics regulate cell behaviors, with a focus on cancer cell biology, epithelial plasticity and more recently neurodegeneration at molecular, cellular, and tissue scales. Her work is recognized for identifying the design principles and functional significance of pH sensors, defined as proteins with activity and ligand binding regulated by cellular pH changes. Her research is supported by several NIH awards and an award from the Paul Allen Family Foundation. Her recent notable honors include being elected as an AAAS Fellow, receiving the Outstanding Faculty Mentoring Award from the UCSF Postdoctoral Scholars Association, and serving as Chair of the Women in Cell Biology (WICB) committee within the American Society for Cell Biology (ASCB).